INTRODUCTION AND OBJECTIVES: Limited data is available regarding the feasibility of robotic-assisted laparoscopic extended pelvic lymph node dissection (RALePLND) for prostate cancer (PC) and the lymph node (LN) yield for each anatomical zone. We aimed to determine the LN yield, distribution patterns and frequency of pelvic LN metastases after RALePLND in men with PC.
INTRODUCTION AND OBJECTIVES: Reliable data on comparisons of open retropubic radical prostatectomy (ORP) vs. robotassisted laparoscopic radical prostatectomy (RARP) is scarce and remains inconclusive.
METHODS: We identified 10,790 consecutive treated patients (7007 ORP vs. 3783 RARP) within our prospective database (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . All procedures were performed by seven highly trained surgeons performing both surgical approaches regularly. Oncological (48-month biochemical recurrence rate [BCR] ), functional (urinary continence, erectile function) and surgical (rate of nerve-sparing procedures, lymph node yield, surgical margin status, length of hospital stay, operation time, blood loss, transfusion rate, time to catheter removal) outcomes were assessed. Kaplan-Meier, multivariable Cox and logistic regression models were used to test for BCR and functional outcome differences.
RESULTS: No statistically significant difference regarding oncological outcome distinguished between ORP vs. RARP. Regarding functional outcomes, one-week continence rates were higher in ORP (25.8% vs. 21.8%, p<0.001). At three months, no statistically significant differences were observed. At one year, continence rates were modestly higher in RARP (90.3% vs. 88.8%, p[0.01) . This effect was no longer observed after stratification for age-groups. Oneyear potency rates were similar in ORP vs. RARP (80.3% vs. 83.6%, p[0.33) . Regarding surgical outcomes, no significant difference was observed in rates of nerve-sparing procedures, lymph node yield, surgical margin status, and length of hospital stay. Conversely, operation time was shorter in ORP, and blood loss, transfusion rates and length of catheter stay were significantly lower in RARP.
CONCLUSIONS: Both surgical approaches, performed in a high-volume center by the same surgeons, achieve excellent, comparable oncological and functional outcomes. However, a slight advantage for RARP regarding surgical outcomes was observed. METHODS: In 5,050 consecutive patients who underwent radical prostatectomy at our institution between 1992 and 2012 the parameters heart disease, hypertension, peripheral vascular disease, lung disease, diabetes, renal disease, liver disease, neurologic disease, tumor, depression, connective tissue disease and AIDS were recorded. The mean patient age was 65 years and the mean follow-up was 10 years. Univariate and multivariable competing risk analyses were used in order to investigate the prognostic significance of single conditions and of the comorbidity index with non-prostate cancer and overall mortality as endpoints.
RESULTS: Eight out of twelve parameters were significant predictors of mortality both in univariate and multivariable analyses. In a sixsided stratification of the index with overall mortality as endpoint, there was a dose response pattern was seen (hazard ratios 1 -1.4 -2.3 -3.8 -79.0 ->1000). With one exception, the neighboring mortality curves differed significantly from each other. In the subgroup of patients with 6 or more concomitant diseases (n[72, 1.4% of patients) the 10-year non-prostate cancer mortality superseded the 50% level. Only two conditions (heart disease, hazard ratio 1.8, p[0.0011 and peripheral vascular disease, hazard ratio 2.0, p[0.0493) were predictors of nonprostate cancer mortality in patients aged 70 years or older.
CONCLUSIONS: The easily applicable unweighed comorbidity index recommended in the ICHOM Standard Set was well suited to predict mortality after radical prostatectomy in the whole sample but was of limited value in patients aged 70 years or older.
